Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Bradley D. Hunter, Michael Rogalski & Caron A. Jacobson. (2019) Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. Expert Opinion on Biological Therapy 19:11, pages 1157-1164.
Read now
Read now
Nancy L. Bartlett, Mitchell R. Smith, Tanya Siddiqi, Ranjana H. Advani, Owen A. O’Connor, Jeff P. Sharman, Tatyana Feldman, Kerry J. Savage, Andrei R. Shustov, Catherine S. Diefenbach, Yasuhiro Oki, Maria Corinna Palanca-Wessels, Mayur Uttarwar, Martha Li, Jing Yang & Eric D. Jacobsen. (2017) Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leukemia & Lymphoma 58:7, pages 1607-1616.
Read now
Read now
Articles from other publishers (22)
Yu Yagi, Yusuke Kanemasa, Yuki Sasaki, Mina Sei, Takuma Matsuo, Kento Ishimine, Yudai Hayashi, Mano Mino, An Ohigashi, Yuka Morita, Taichi Tamura, Shohei Nakamura, Toshihiro Okuya, Takuya Shimizuguchi, Naoki Shingai, Takashi Toya, Hiroaki Shimizu, Yuho Najima, Takeshi Kobayashi, Kyoko Haraguchi, Noriko Doki, Yoshiki Okuyama & Tatsu Shimoyama. (2023) Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study. Cancer Medicine.
Crossref
Crossref
Peter A. Riedell, Wei-Ting Hwang, Loretta J. Nastoupil, Martina Pennisi, Joseph P. McGuirk, Richard T. Maziarz, Veronika Bachanova, Olalekan O. Oluwole, Jamie Brower, Oscar A. Flores, Nausheen Ahmed, Levanto Schachter, Kharmen Bharucha, Bhagirathbhai R. Dholaria, Stephen J. Schuster, Miguel-Angel Perales, Michael R. Bishop & David L. Porter. (2022) Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. Transplantation and Cellular Therapy 28:10, pages 669-676.
Crossref
Crossref
Joseph E Maakaron, Marie Hu & Najla El Jurdi. (2022) Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations. BMJ, pages e068956.
Crossref
Crossref
Mussadique Ali Jhatial, Manzoor Khan, Saif ur Rab, Naila Shaikh, Chandumal Loohana & Syed W Imam. (2021) Outcomes of Diffuse Large B-Cell Non-Hodgkin’s Lymphoma After Gemcitabine-Based Second Salvage Chemotherapy: A Single-Center Study. Cureus.
Crossref
Crossref
Junxia Hu, Xin Wang, Fei Chen, Mengjie Ding, Meng Dong, Wanqiu Yang, Meifeng Yin, Jingjing Wu, Lei Zhang, Xiaorui Fu, Zhenchang Sun, Ling Li, Xinhua Wang, Xin Li, Shuangshuang Guo, Dianbao Zhang, Xiaohui Lu, Qing Leng, Mingzhi Zhang, Linan Zhu, Xudong Zhang & Qingjiang Chen. (2021) Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure. Frontiers in Oncology 11.
Crossref
Crossref
Caron A. Jacobson, Bradley D. Hunter, Robert Redd, Scott J. Rodig, Pei-Hsuan Chen, Kyle Wright, Mikel Lipschitz, Jerome Ritz, Yusuke Kamihara, Philippe Armand, Sarah Nikiforow, Michael Rogalski, Joseph Maakaron, Samantha Jaglowski, Marcela V. Maus, Yi-Bin Chen, Jeremy S. Abramson, Justin Kline, Elizabeth Budde, Alex Herrera, Matthew Mei, Jonathon B. Cohen, Stephen D. Smith, David G. Maloney, Ajay K. Gopal, Matthew J. Frigault & Utkarsh H. Acharya. (2020) Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. Journal of Clinical Oncology 38:27, pages 3095-3106.
Crossref
Crossref
Fang Bao, Wei Wan, Ting He, Feifei Qi, Guanghua Liu, Kai Hu, Xin-an Lu, Ping Yang, Fei Dong, Jing Wang & Hongmei Jing. (2019) Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma. Cancer Gene Therapy 26:7-8, pages 248-255.
Crossref
Crossref
Miriam Marangon, Vittorio Stefoni, Alessia Castellino, Carlo Visco, Monica Tani, Maria Christina Cox, Roberto Marasca, Cristina Tecchio, Liliana Devizzi, Federico Monaco, Alessandra Romano, Chiara Rusconi, Luigi Rigacci, Claudia Castellino, Francesco Gaudio, Lisa Argnani & Pier Luigi Zinzani. (2019) Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience. Clinical Lymphoma Myeloma and Leukemia 19:7, pages e321-e323.
Crossref
Crossref
LaQuisa Hill, Premal Lulla & Helen E Heslop. (2019) CAR‐T cell therapy for non‐Hodgkin lymphomas: A new treatment paradigm. ADVANCES IN CELL AND GENE THERAPY 2:3.
Crossref
Crossref
Yu Cai, Liping Wan, Juan Yang, Jun Zhu, Jieling Jiang, Su Li, Xianmin Song & Chun Wang. (2019) High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma. Annals of Hematology 98:4, pages 823-831.
Crossref
Crossref
Ranjit Nair & Sattva S. Neelapu. (2018) The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Practice & Research Clinical Haematology 31:3, pages 293-298.
Crossref
Crossref
Jennifer N. Brudno & James N. Kochenderfer. (2017) Chimeric antigen receptor T-cell therapies for lymphoma. Nature Reviews Clinical Oncology 15:1, pages 31-46.
Crossref
Crossref
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick J. Stiff, Jonathan W. Friedberg, Ian W. Flinn, Andre Goy, Brian T. Hill, Mitchell R. Smith, Abhinav Deol, Umar Farooq, Peter McSweeney, Javier Munoz, Irit Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chavez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Thomas E. Witzig, Patrick Reagan, Adrian Bot, John Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek & William Y. Go. (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine 377:26, pages 2531-2544.
Crossref
Crossref
Sarah C. Rutherford & John P. Leonard. (2017) Lymphoma “benchmark” or “bench-smudge”?. Blood 130:16, pages 1778-1779.
Crossref
Crossref
Michael CrumpSattva S. NeelapuUmar FarooqEric Van Den NesteJohn KuruvillaJason WestinBrian K. LinkAnnette HayJames R. Cerhan, Liting ZhuSami BoussettaLei FengMatthew J. Maurer, Lynn Navale, Jeff Wiezorek, William Y. Go & Christian Gisselbrecht. (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130:16, pages 1800-1808.
Crossref
Crossref
Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chavez, Chitra M. Hosing, Armin Ghobadi, Lihua E. Budde, Adrian Bot, John M. Rossi, Yizhou Jiang, Allen X. Xue, Meg Elias, Jeff Aycock, Jeff Wiezorek & William Y. Go. (2017) Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy 25:1, pages 285-295.
Crossref
Crossref
Michael Crump. (2016) Management of Relapsed Diffuse Large B-cell Lymphoma. Hematology/Oncology Clinics of North America 30:6, pages 1195-1213.
Crossref
Crossref
E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, N Milpied, J Radford, N Ketterer, O Shpilberg, U Dührsen, D Ma, J Brière, C Thieblemont, G Salles, C H Moskowitz, B Glass & C Gisselbrecht. (2015) Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplantation 51:1, pages 51-57.
Crossref
Crossref
Eric D. JacobsenJeff P. SharmanYasuhiro OkiRanjana H. AdvaniJane N. WinterCeleste M. BelloGary SpitzerMaria Corinna Palanca-Wessels, Dana A. Kennedy, Pamela Levine, Jing Yang & Nancy L. Bartlett. (2015) Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 125:9, pages 1394-1402.
Crossref
Crossref
Jason R. Westin, Peter McLaughlin, Jorge Romaguera, Fredrick B. Hagemeister, Barbara Pro, Nam H. Dang, Felipe Samaniego, Maria A. Rodriguez, Luis Fayad, Yasuhiro Oki, Michelle Fanale, Nathan Fowler, Loretta Nastoupil, Lei Feng, Evelyn Loyer & Anas Younes. (2014) Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. British Journal of Haematology 167:2, pages 177-184.
Crossref
Crossref
Guili Hu, Yang Liu, Hong Li, Dekuang Zhao, Liuqing Yang, Jiangen Shen, Xuejun Hong, Xuetao Cao & Qingqing Wang. (2010) Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effect. Cellular & Molecular Immunology 7:4, pages 296-305.
Crossref
Crossref
Rebecca L. Elstrom, Peter Martin, Katya Ostrow, Jacqueline Barrientos, Amy Chadburn, Richard Furman, Jia Ruan, Tsiporah Shore, Michael Schuster, Leandro Cerchietti, Ari Melnick, Morton Coleman & John P. Leonard. (2010) Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies. Clinical Lymphoma Myeloma and Leukemia 10:3, pages 192-196.
Crossref
Crossref